Voyager Therapeutics Inc [VYGR] stock is trading at $3.29, up 20.07%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The VYGR shares have gain 12.67% over the last week, with a monthly amount drifted -7.32%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citigroup started tracking the stock with Buy rating on December 02, 2024, and set its price target to $12. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $15 on October 16, 2024. Guggenheim initiated its recommendation with a Buy and recommended $22 as its price target on March 26, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on March 19, 2024, and assigned it a price target of $30. In a note dated March 07, 2024, Citigroup initiated an Buy rating and provided a target price of $16 on this stock.
Voyager Therapeutics Inc [VYGR] stock has fluctuated between $2.64 and $9.55 over the past year. Currently, Wall Street analysts expect the stock to reach $10 within the next 12 months. Voyager Therapeutics Inc [NASDAQ: VYGR] shares were valued at $3.29 at the most recent close of the market. An investor can expect a potential return of 203.95% based on the average VYGR price forecast.
Analyzing the VYGR fundamentals
Voyager Therapeutics Inc [NASDAQ:VYGR] reported sales of 66.96M for the trailing twelve months, which represents a drop of -66.83%. Gross Profit Margin for this corporation currently stands at 0.37% with Operating Profit Margin at -1.0%, Pretax Profit Margin comes in at -1.25%, and Net Profit Margin reading is -1.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.27 and Total Capital is -0.21. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.05 points at the first support level, and at 2.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.63, and for the 2nd resistance point, it is at 3.97.
Ratios To Look Out For
For context, Voyager Therapeutics Inc’s Current Ratio is 6.10. Further, the Quick Ratio stands at 6.10, while the Cash Ratio is 1.86. Considering the valuation of this stock, the price to sales ratio is 2.72, the price to book ratio is 0.67.
Transactions by insiders
Recent insider trading involved Ferguson Toby, Chief Medical Officer, that happened on Apr 02 ’25 when 10086.0 shares were sold. President and CEO, Sandrock Alfred completed a deal on Apr 02 ’25 to sell 10885.0 shares. Meanwhile, Officer Sandrock Alfred bought 10885.0 shares on Apr 02 ’25.
